Readnour Robin Shane sold ANTX

January 12, 2024 · Form 4 insider transaction

Readnour Robin Shane sold 719 shares of AN2 Therapeutics, Inc. at $21.91 per share, a transaction worth $15.8K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 5 days after the transaction.

Direction
Disposed (sell-side)
Shares
719
Price
$21.91
Total value
$15.8K
RoleDirector
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateJanuary 12, 2024
Filing dateJanuary 17, 2024
Shares owned after485,073
OwnershipIndirect
10b5-1 planYes
AmendedNo

Footnotes

The reported sale of 719 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC 2018 QP on August 30, 2023.; This price represents the weighted average sale price (rounded to the nearest cent) for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $21.90 to $21.99. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price.; MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.; Shares held directly by MGC 2018 QP.

View the original Form 4 on SEC EDGAR